Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
FULC Fulcrum Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: FULC
Price (delayed)
$5.41
Market cap
$292.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.01
Enterprise value
$256.75M
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine
Highlights
Fulcrum Therapeutics's net income has soared by 99% YoY and by 95% from the previous quarter
The company's EPS has surged by 99% YoY and by 94% QoQ
The equity has grown by 7% YoY but it has contracted by 6% from the previous quarter
Key stats
What are the main financial stats of FULC
Market
Valuations
Earnings
Shares outstanding
53.98M
Market cap
$292.03M
Enterprise value
$256.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.28
Price to sales (P/S)
4.23
EV/EBIT
N/A
EV/EBITDA
268.29
EV/Sales
3.21
Revenue
$80M
Gross profit
$80M
Operating income
-$12.47M
Net income
-$510,000
EBIT
-$510,000
EBITDA
$957,000
Free cash flow
$7.56M
Per share
Balance sheet
Liquidity
EPS
-$0.01
EPS diluted
-$0.03
Free cash flow per share
$0.12
Book value per share
$4.23
Revenue per share
$1.28
TBVPS
$3.88
Total assets
$242.65M
Total liabilities
$14.16M
Debt
$8.11M
Equity
$228.49M
Working capital
$224.46M
Debt to equity
0.04
Current ratio
28.71
Quick ratio
28.24
Net debt/EBITDA
-36.86
Margins
Efficiency
Dividend
EBITDA margin
1.2%
Gross margin
100%
Net margin
-0.6%
Operating margin
-15.6%
Return on assets
-0.2%
Return on equity
-0.2%
Return on invested capital
-0.3%
Return on capital employed
-0.2%
Return on sales
-0.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FULC stock price
How has the Fulcrum Therapeutics stock price performed over time
Intraday
6.71%
1 week
23.52%
1 month
104.92%
1 year
-28.72%
YTD
15.11%
QTD
87.85%
Financial performance
How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$80M
Gross profit
$80M
Operating income
-$12.47M
Net income
-$510,000
Gross margin
100%
Net margin
-0.6%
Fulcrum Therapeutics's operating margin has soared by 100% YoY and by 43% from the previous quarter
The net margin has soared by 100% YoY and by 95% from the previous quarter
Fulcrum Therapeutics's net income has soared by 99% YoY and by 95% from the previous quarter
The company's operating income has surged by 89% YoY and by 43% QoQ
Price vs fundamentals
How does FULC's price correlate with its fundamentals
Growth
What is Fulcrum Therapeutics's growth rate over time
Valuation
What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
1.28
P/S
4.23
EV/EBIT
N/A
EV/EBITDA
268.29
EV/Sales
3.21
The company's EPS has surged by 99% YoY and by 94% QoQ
FULC's P/B is 42% below its 5-year quarterly average of 2.2 but 28% above its last 4 quarters average of 1.0
The equity has grown by 7% YoY but it has contracted by 6% from the previous quarter
The price to sales (P/S) is 93% lower than the 5-year quarterly average of 57.2 but 28% higher than the last 4 quarters average of 3.3
Efficiency
How efficient is Fulcrum Therapeutics business performance
Fulcrum Therapeutics's ROE has soared by 100% YoY and by 95% from the previous quarter
The company's return on sales has surged by 100% YoY and by 95% QoQ
FULC's return on invested capital has surged by 99% year-on-year and by 94% since the previous quarter
Fulcrum Therapeutics's ROA has soared by 99% YoY and by 94% from the previous quarter
Dividends
What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FULC.
Financial health
How did Fulcrum Therapeutics financials performed over time
Fulcrum Therapeutics's quick ratio has increased by 41% YoY and by 28% from the previous quarter
The current ratio has grown by 41% year-on-year and by 27% since the previous quarter
The debt is 96% less than the equity
The debt to equity is down by 20% year-on-year
The debt has contracted by 20% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.